Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
RBN-2397
DRUG
2 trials
Sponsors
Ribon Therapeutics, Inc.
Conditions
Advanced Squamous Non-Small Cell Lung Carcinoma
Solid Tumor, Adult
Phase 1
Phase 1 Study of RBN-2397, an Oral PARP7 Inhibitor, in Patients With Solid Tumors
NCT04053673
Ribon Therapeutics, Inc.
Solid Tumor, Adult
Start: 2019-08-01
End: 2023-07-31
Target: 130
Updated: 2023-03-28
RBN-2397 in Combination With Pembrolizumab in Patients With SCCL
NCT05127590
Ribon Therapeutics, Inc.
Advanced Squamous Non-Small Cell Lung Carcinoma
Start: 2022-03-15
End: 2023-12-31
Target: 50
Updated: 2023-07-03
Related Papers
Abstract B072: Induction of PARP7 creates a vulnerability for growth inhibition by RBN2397 in prostate cancer cells
Cancer Research
2023-06-02
Abstract CT109: First-in-class first-in-human phase 1 trial and translational study of the mono(ADP-ribose) polymerase-7 (PARP7) inhibitor RBN-2397 in patients with selected advanced solid tumors
Cancer Research
2023-04-14
2 citations
Abstract 2508: Clinical significance of PARP7 (<i>TIPARP</i>) gene copy number alterations in human non-small cell and head & neck carcinomas
Cancer Research
2023-04-04
Abstract 2154: PARP7 inhibitor RBN-2397 increases tumoral IFN signaling leading to various tumor cell intrinsic effects and tumor regressions in mouse models
Cancer Research
2022-06-15
2 citations
Abstract 1836: RBN-2397, a novel, potent, and selective PARP7 inhibitor, induces tumor-intrinsic type I interferon responses and adaptive immunity in patient tumors
Cancer Research
2022-06-15
1 citations
866 RBN-2397, a novel, potent, and selective PARP7 inhibitor, induces tumor-intrinsic type I interferon responses and adaptive immunity in preclinical models and patient tumors
Regular and Young Investigator Award Abstracts
2021-11-01
5 citations
Abstract 48: RBN-2397: A potent and selective small molecule inhibitor of PARP7 that induces tumor-derived antitumor immunity dependent on CD8 T cells
Cancer Research
2021-07-01
2 citations
A first-in-human phase 1 study of a novel PARP7 inhibitor RBN-2397 in patients with advanced solid tumors.
Journal of Clinical Oncology
2021-05-20
16 citations